Autologous Fat Grafting to the Breast
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Women's Studies |
| Therapuetic Areas: | Oncology, Reproductive |
| Healthy: | No |
| Age Range: | 17 - 70 |
| Updated: | 4/2/2016 |
| Start Date: | June 2008 |
| End Date: | June 2010 |
| Contact: | Kamran Khoobehi, MD |
| Phone: | 504-779-5538 |
Structural fat grafting is a form of tissue transfer where the autologous fat is harvested
and subsequently transferred to a different region of the body at the same setting. It is an
excellent technique for filling soft tissue and contour defects. Fat has the benefit of
being abundantly available and easy to harvest. Further more, it is cheap and autogenous and
thus lacks the side effects of synthetic fillers or implants. Autogenous fat transfer is a
relatively common procedure performed by plastic and reconstructive surgeons. The goal of
fat grafting is to provide the patient with a predictable, long lasting autogenous soft
tissue augmentation. Autogenous fat transfer has been used extensively as an adjunct to
facial rejuvenation. As well it has been applied to body contouring and augmentation of the
hips, trochanteric areas, thighs and buttocks, back, torso and breast. The transfer of
autologous fat dates back to 1890s and more specifically as injectable grafts since the
1920s. However, over the past 20 years the popularity of structural fat grafting has
increased as a contouring modality. Fat transfer to the breast, popularized by Coleman, has
been performed internationally since the 1990s. Despite the duration, the literature lacks
accurate outcomes data on fat transfer to the breast and questions regarding the viability
of adipocytes after the transfer exist. Sources from various publications show cell
viability of up to 100% however studies of long term clinical outcomes quote rates of 10% to
80%.
and subsequently transferred to a different region of the body at the same setting. It is an
excellent technique for filling soft tissue and contour defects. Fat has the benefit of
being abundantly available and easy to harvest. Further more, it is cheap and autogenous and
thus lacks the side effects of synthetic fillers or implants. Autogenous fat transfer is a
relatively common procedure performed by plastic and reconstructive surgeons. The goal of
fat grafting is to provide the patient with a predictable, long lasting autogenous soft
tissue augmentation. Autogenous fat transfer has been used extensively as an adjunct to
facial rejuvenation. As well it has been applied to body contouring and augmentation of the
hips, trochanteric areas, thighs and buttocks, back, torso and breast. The transfer of
autologous fat dates back to 1890s and more specifically as injectable grafts since the
1920s. However, over the past 20 years the popularity of structural fat grafting has
increased as a contouring modality. Fat transfer to the breast, popularized by Coleman, has
been performed internationally since the 1990s. Despite the duration, the literature lacks
accurate outcomes data on fat transfer to the breast and questions regarding the viability
of adipocytes after the transfer exist. Sources from various publications show cell
viability of up to 100% however studies of long term clinical outcomes quote rates of 10% to
80%.
Our goal with this study is to prospectively acquire information with our protocol that will
outline the accurate long-term outcomes of fat transfer to the breast. Currently, fat
grafting to the breast is a treatment option in conditions such as micromastia, breast
ptosis, post mastectomy breast reconstruction, asymmetric breasts, congenital malformations
of breast development and for treatment of complications associated with implant
augmentation mammoplasty. In addition to fat grafting, the current surgical treatment for
these conditions is mainly based on techniques requiring implant augmentation or
reconstruction. Although the safety of saline implants has been well studied and documented,
this data cannot be extrapolated for the newer generation silicone implants and other
alternatives such as fat grafting need to be investigated. Also implant augmentation and
reconstruction comes at the price of capsular contracture, implant deflation, infection and
more future corrective surgeries. We plan to prospectively study the outcomes of fat
grafting in patients with these conditions for a period of 5 years. The collected
information will be entered into a database and will be prospectively collected and
reviewed. Patients demographics, information obtained during the preoperative and
postoperative visits along with the pertinent findings regarding the fat transfer to the
breast will be collected into the database for our investigation.
outline the accurate long-term outcomes of fat transfer to the breast. Currently, fat
grafting to the breast is a treatment option in conditions such as micromastia, breast
ptosis, post mastectomy breast reconstruction, asymmetric breasts, congenital malformations
of breast development and for treatment of complications associated with implant
augmentation mammoplasty. In addition to fat grafting, the current surgical treatment for
these conditions is mainly based on techniques requiring implant augmentation or
reconstruction. Although the safety of saline implants has been well studied and documented,
this data cannot be extrapolated for the newer generation silicone implants and other
alternatives such as fat grafting need to be investigated. Also implant augmentation and
reconstruction comes at the price of capsular contracture, implant deflation, infection and
more future corrective surgeries. We plan to prospectively study the outcomes of fat
grafting in patients with these conditions for a period of 5 years. The collected
information will be entered into a database and will be prospectively collected and
reviewed. Patients demographics, information obtained during the preoperative and
postoperative visits along with the pertinent findings regarding the fat transfer to the
breast will be collected into the database for our investigation.
Inclusion Criteria:
- Women with the following conditions micromastia, breast ptosis, post mastectomy
breast reconstruction, asymmetric breasts, congenital malformations of breast
development and for treatment of complications associated with implant augmentation
mammoplasty.
Exclusion Criteria:
- A volunteer who has a positive pregnancy test
- A volunteer who has had a cardiac stent placed within the last two months
- A volunteer with a known, current substance abuse
- A volunteer with a bleeding diathesis
- Untreated breast cancer
- A volunteer who smokes cigarettes
- Medical Conditions including untreated hypertension, renal disease, diabetes mellitus
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials